Last reviewed · How we verify
Voluven (HES 130/0.4)
Voluven (HES 130/0.4) is a colloid volume expander used to increase blood volume.
Voluven (HES 130/0.4) is a colloid volume expander used to increase blood volume. Used for Volume expansion in adults and children with hypovolemia due to trauma, surgery, or burns.
At a glance
| Generic name | Voluven (HES 130/0.4) |
|---|---|
| Also known as | 6% HES 130/0.4, 6% hetastarch solution, Voluven |
| Sponsor | Sangart |
| Drug class | Colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by increasing the amount of fluid in the blood vessels, which helps to improve blood pressure and increase blood flow to vital organs. This can be particularly useful in situations where there is significant blood loss or fluid loss, such as during surgery or in cases of severe burns.
Approved indications
- Volume expansion in adults and children with hypovolemia due to trauma, surgery, or burns
Common side effects
- Hypersensitivity reactions
- Anaphylaxis
- Cardiovascular instability
Key clinical trials
- Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients (NA)
- Cardiac Output in Preeclamptic (NA)
- Optimizing Fluid Resuscitation in Adults With Major Burns: A Randomized Trial of Burn Navigator™ Versus Parkland Formula (PHASE4)
- Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : Pilot Study in Adult Elective Conventional Cardiac Surgery (PHASE3)
- Colloid Infusion for Optimal Outcomes In Non-cardiac Surgery (COIN Trial) (NA)
- Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voluven (HES 130/0.4) CI brief — competitive landscape report
- Voluven (HES 130/0.4) updates RSS · CI watch RSS
- Sangart portfolio CI